



- CAB showed statistically significant prognostication of HR+/HER2- EBCs in **global validation** studies:
 - i. In **young, N+, low-ER and ET-alone treated** patients
 - ii. Prospective-randomised TEAM trial (completed trial data)
 - iii. **Real-world** usefulness on ~10000+ patients with early NPV >95%.
- Backed by the data, **CAB** emerges as a **reliable and cost-effective solution** for patients in India and worldwide.